Mark Underwood

Dr. Mark Underwood

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
MUMark Underwood
Mark Underwood
JHJoe Horton
Joe Horton
KNKeith Nangle
Keith Nangle
JHJudy Hopking
Judy Hopking
KSKimberly Smith
Kimberly Smith
RWRuolan Wang
Ruolan Wang
At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic suppression in adults with HIV-1 who failed first-line therapy. Here, we report emergent HIV-1 drug resistance and mechanistic underpinnings among dolutegravir-treated adults in DAWNING.

14 February 2020 in Applied Ontology
Verified
Journal Article
Closed access
PDF file
KBKenneth Baclawski
Kenneth Baclawski
MBMike Bennett
Mike Bennett
GBGary Berg-Cross
Gary Berg-Cross
DFDonna Fritzsche
Donna Fritzsche
RSRavi Sharma
Ravi Sharma
DWDavid G. Whitten
David G. Whitten
With the increasing amount of software devoted to industrial automation and process control, it is becoming more important than ever for systems to be able to explain their behavior. In some domains, such as financial services, explainability is mand

11 June 2023 in Viruses
Verified
Journal Article
Open access
PDF file
RWRuolan Wang
Ruolan Wang
JWJonathan Wright
Jonathan Wright
PSParminder Saggu
Parminder Saggu
MAMounir Ait-Khaled
Mounir Ait-Khaled
RMRiya Moodley
Riya Moodley
MUMark Underwood
Mark Underwood
The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot. A total of 320 (86%) participants on DTG/3TC and 318 (85%) on TBR had both proviral genotype data and ≥1 on-treatment post-baseline VL results and were defined as the proviral DNA resistance analysis population. Archived International AIDS Society–USA major nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, and integrase strand transfer inhibitor resistance-associated mutations (RAMs) were observed in 42 (7%), 90 (14%), 42 (7%), and 11 (2%) participants, respectively, across both groups; 469 (74%) had no major RAMs at baseline. M184V/I (1%), K65N/R (99% of participants on DTG/3TC and 99% on TBR were virologically suppressed (last on-treatment VL <50 copies/mL) regardless of the presence of major RAMs. Results from the sensitivity analysis by Snapshot were consistent with the last available on-treatment VL. In TANGO, archived, pre-existing major RAMs did not impact virologic outcomes through week 144.

6 March 2024 in Viruses
Verified
Journal Article
Open access
PDF file
MUMark Underwood
Mark Underwood
RURimgaile Urbaityte
Rimgaile Urbaityte
RWRuolan Wang
Ruolan Wang
JHJoe Horton
Joe Horton
JOJames Oyee
James Oyee
JSJörg Sievers
Jörg Sievers
In GEMINI-1/-2, dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in achieving viral suppression (viral load [VL] < 50 copies/mL) in treatment-naive adults. Abbott’s RealTime HIV-1 assay provides quantitative VL (40–10,000,000 copies/mL) and qualitative target detected or target not detected (TND) for VL < 40 copies/mL. This post hoc analysis assessed very-low-level viremia and “blips” through Week 144. Proportions with VL < 40 copies/mL and TND are presented overall and by baseline VL and CD4+ cell count. “Blips” (single VL ≥ 50 to <200 copies/mL with adjacent values < 50 copies/mL) were assessed from Day 1 after VL suppression and from Weeks 48 through to 144. Proportions with TND increased through Week 48 and were similar between groups at all visits (Week 144: dolutegravir + lamivudine, 451/716 [63%]; dolutegravir + TDF/FTC, 465/717 [65%]). By observed analysis, TND rates were similar between groups across baseline subgroups. Through Week 144, proportions with ≥1 “blip” were generally comparable for dolutegravir + lamivudine vs. dolutegravir + TDF/FTC from Day 1 (15% vs. 20%) and from Week 48 (7% vs. 11%). Through 144 weeks, the proportions with TND or “blips” were similar between dolutegravir + lamivudine and the three-drug comparator, reinforcing the efficacy and durability of dolutegravir + lamivudine.

2 December 2015 in Applied Ontology
Verified
Journal Article
Closed access
PDF file
MUMark Underwood
Mark Underwood
MGMichael Gruninger
Michael Gruninger
LOLeo Obrst
Leo Obrst
KBKen Baclawski
Ken Baclawski
MBMike Bennett
Mike Bennett
RSRam Sriram
Ram Sriram

16 February 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
MUMark Underwood
Mark Underwood
JHJoe Horton
Joe Horton
KNKeith Nangle
Keith Nangle
JHJudy Hopking
Judy Hopking
KSKimberly Smith
Kimberly Smith
RWRuolan Wang
Ruolan Wang